A groundbreaking urine test for lung cancer, which detects 'zombie' cell proteins, could be available for NHS use within five years. This test aims to identify early signs of lung cancer, enabling diagnosis months or even years before symptoms manifest. Most lung cancer cases in England are diagnosed at advanced stages, making treatment more challenging. The research, supported by Cancer Research UK, has recently cleared a significant hurdle, moving closer to clinical application. Professor Ljiljana Fruk from the University of Cambridge expressed optimism about the test's potential to be integrated into GP surgeries and hospitals, significantly impacting early cancer detection. The sensor developed interacts with proteins from senescent cells, known for their role in promoting cancer. Researchers validated this biomarker using patient samples and genetic data, with hopes of expanding its use to detect other conditions like pulmonary fibrosis. The next steps involve clinical trials to ensure efficacy before widespread implementation.